Tranexamic Acid for Hyperpigmentation Disorders: A Literature Review on Efficacy and Safety in Melasma and PIH
Journal of Cosmetic Dermatology · 2026
DOI: 10.1111/jocd.70692 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cosmetic Dermatology, 2026. Verfasst von Ahmed AlJabr und 2 weiteren Autor:innen. Beteiligte Einrichtung: Habib Medical Center, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Tranexamic Acid, Melanosis, Hyperpigmentation, Antifibrinolytic Agents. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Hyperpigmentation disorders, including melasma and post‐inflammatory hyperpigmentation (PIH), are common dermatologic conditions associated with significant cosmetic and psychological burden. Tranexamic acid (TXA), an antifibrinolytic agent, has gained increasing attention due to its anti‐inflammatory and antimelanogenic properties.
Objective
To review the current evidence on the efficacy and safety of tranexamic acid in the management of hyperpigmentation disorders, particularly melasma and PIH.
Methods
A narrative literature review was conducted using PubMed, Scopus, and Google Scholar to identify clinical and observational studies evaluating the efficacy, safety, and comparative outcomes of oral, topical, and intradermal tranexamic acid in hyperpigmentation disorders. Data were descriptively analyzed with comparison to standard treatments such as hydroquinone and laser therapies.
Results
Evidence from randomized and comparative studies demonstrates that oral, topical, and intradermal TXA significantly reduce pigmentation indices and improve quality‐of‐life scores in patients with melasma and PIH. Oral TXA at doses of 250–500 mg twice daily showed sustained clinical improvement with minimal adverse effects, most commonly mild gastrointestinal symptoms and menstrual irregularities. Topical and intradermal formulations demonstrated comparable or superior efficacy to hydroquinone with fewer irritant reactions. Combination therapies (e.g., TXA with hydroquinone or laser) yielded enhanced and longer‐lasting outcomes.
Conclusion
Tranexamic acid represents a promising and well‐tolerated therapeutic option for hyperpigmentation disorders. Its efficacy across multiple administration routes, favorable safety profile, and synergistic potential with existing therapies support its expanding role as both a primary and adjunctive treatment in dermatologic pigment management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Habib Medical Center, Riyadh, Saudi Arabia.
- College of Medicine, Dar Al Uloom University, Riyadh, Saudi Arabia.
ORCID-Profile: Rakan Abdulkarim A AlEtebi
Zitieren
APA
AlJabr, A., AlAnazi, A. M. I., & AlEtebi, R. A. A. (2026). Tranexamic Acid for Hyperpigmentation Disorders: A Literature Review on Efficacy and Safety in Melasma and PIH. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70692
Vancouver
AlJabr A, AlAnazi AMI, AlEtebi RAA. Tranexamic Acid for Hyperpigmentation Disorders: A Literature Review on Efficacy and Safety in Melasma and PIH. Journal of Cosmetic Dermatology. 2026. doi:10.1111/jocd.70692
BibTeX
@article{AlJabr2026,
author = {AlJabr, Ahmed and AlAnazi, Aseel Muhana I and AlEtebi, Rakan Abdulkarim A},
title = {Tranexamic Acid for Hyperpigmentation Disorders: A Literature Review on Efficacy and Safety in Melasma and PIH},
journal = {Journal of Cosmetic Dermatology},
year = {2026},
doi = {10.1111/jocd.70692}
}
EUVIMED